![free clinical trials for acute myeloid leukemia free clinical trials for acute myeloid leukemia](https://news.weill.cornell.edu/sites/default/files/styles/news_story_featured_image/public/story_featured_images/shutterstock_570582916.jpg)
#Free clinical trials for acute myeloid leukemia trial
![free clinical trials for acute myeloid leukemia free clinical trials for acute myeloid leukemia](https://smallcaps.com.au/wp-content/uploads/2020/06/Race-Oncology-ASX-RAC-Acute-Myeloid-Leukaemia-bisantrene-Phase-2-clinical-trial.jpg)
The purpose of this study is to determine the safety and preliminary effiectiveness of voruciclib in subjects with relapsed/refractory B cell malignancies or AML after treatment with standard therapy. A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML.Giving antithymocyte globulin before transplant and cyclosporine, tacrolimus, and methotrexate before and after transplant may stop this from happening. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells.
![free clinical trials for acute myeloid leukemia free clinical trials for acute myeloid leukemia](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/dbe114d6-dd9b-487b-a8d8-749d32644930/gr1.jpg)
The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). It also stops the patient's immune system from rejecting the donor's stem cells. RATIONALE: Giving chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells. A Study of Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia, or Refractory or Relapsed Acute Myelogenous Leukemia.
![free clinical trials for acute myeloid leukemia free clinical trials for acute myeloid leukemia](https://image3.slideserve.com/6417476/slide1-l.jpg)
This first-in-human clinical trial is a Phase 1/1b, open-label, sequential-group, dose-escalation and cohort expansion study evaluating the safety, and antitumor activity of FLX925 in people with relapsed or refractory Acute Myeloid Leukemia. Scottsdale/Phoenix, AZ Jacksonville, FL Rochester, MN First-in-Human Study of FLX925 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia.The purpose of this study is to determine a recommended phase 2 dose (RP2D) of pevonedistat, azacitidine (or decitabine), and venetoclax to treat Acute Myelogenous Leukemia. A Study to Evaluate Pevonedistat, Azacitidine (or Decitabine), and Venetoclax (PAVE) to Treat Acute Myelogenous Leukemia (AML) Patients.It is not yet known which combination chemotherapy is more. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells. Drugs used in chemotherapy, such as cytarabine, daunorubicin hydrochloride, idarubicin, and vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing. This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute myeloid leukemia. Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia.Phase II will confirm the dose and schedule of eltrombopag identified in Phase I that can increase platelet counts in patients receiving consolidation therapy. After the maximum safe and tolerated dose and schedule is found in Phase I, the study will proceed to Phase II. Phase I will study the side effects, best dose and platelet effects of eltrombopag when given with consolidation chemotherapy. Eltrombopag may help increase the number of platelets during chemotherapy and may help prevent the risk of bleeding. Patients with Acute Myeloid Leukemia (AML) in complete remission will receive eltrombopag while undergoing consolidation chemotherapy with high-dose cytarabine. Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission.